1.0The Texas Heart Institute®https://www.texasheart.orgDaynene Vykoukalhttps://www.texasheart.org/author/daynene/ARTEMIS (NCT06118281)rich600338<blockquote class="wp-embedded-content" data-secret="qrwzq8OasU"><a href="https://www.texasheart.org/research/clinical-trials/artemis-nct06118281/">ARTEMIS (NCT06118281)</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.texasheart.org/research/clinical-trials/artemis-nct06118281/embed/#?secret=qrwzq8OasU" width="600" height="338" title="“ARTEMIS (NCT06118281)” — The Texas Heart Institute®" data-secret="qrwzq8OasU" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
The aim of the ARTEMIS study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST elevation and non-ST-elevation myocardial infarction (MI).https://www.texasheart.org/wp-content/uploads/2018/01/forefront-of-discovery.jpg20481083